Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q1 EPS of ($0.18), $0.07 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $34.4 million versus the consensus estimate of $28.12 million.

GUIDANCE:

Aurinia Pharmaceuticals sees FY2023 revenue of $135-155 million, versus the consensus of $142.7 million.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.